🔎 Trials Near Me

Home › Chronic Lymphocytic Leukemia › North Carolina

Chronic Lymphocytic Leukemia clinical trials in North Carolina

35 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in North Carolina.

Cities in North Carolina

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 109, Greenville
  • GC2202 Decentralized Study Site 114, Morrisville
  • GC2202 Study Site 117, Wilson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05645107

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Duke University Medical Center, Durham
  • and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04269902

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  • Duke Adult Blood and Marrow Clinic, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07342478

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • East Carolina University, Greenville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06588478

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • AdventHealth Infusion Center Asheville, Asheville
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • AdventHealth Infusion Center Haywood, Clyde
  • and 6 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Duke University Medical Center, Durham
  • Margaret R Pardee Memorial Hospital, Hendersonville
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Nov 3, 2026 · NCT07321652

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • Duke University, Durham
  • Novant Health Cancer Institute, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07221500

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • Durham VA Medical Center, Durham, NC, Durham
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 30, 2026 · NCT06520098

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  • Research Site, Charlotte
  • Research Site, Charlotte
  • Research Site, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06564038

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579

MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

  • Research Site, Charlotte
  • Research Site, Durham
  • Research Site, Winston-Salem
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Oct 23, 2026 · NCT07024706

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • University of North Carolina At Chapel Hill, Chapel Hill
  • Levine Cancer Center, Charlotte
  • Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06943872

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

  • The University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06043674

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Duke University, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  • Carolina Oncology Specialists, PA ( Site 0054), Charlotte
  • Southeastern Medical Oncology Center ( Site 0049), Goldsboro
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06136559

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT07061951

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  • Research Site, Charlotte
  • Research Site, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  • Atrium Health Levine Cancer Institute (Lci), Charlotte
  • Duke University Medical Center, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • University of North Carolina At Chapel Hill, Chapel Hill
  • Atrium Health Levine Cancer Institute (Lci), Charlotte
  • Duke University Medical Center, Durham
  • and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • UNC School of Medicine, Division of Hematology, Chapel Hill
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

  • University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

  • North Carolina Basnight Cancer Hospital, Chapel Hill
Recruiting
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06860880

Registry of Older Patients With Cancer

  • Seby B. Jones Cancer Center, Boone
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
  • East Carolina University, Greenville
  • and 4 more
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

  • Wake Forest Baptist Health, Winston-Salem
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Apr 13, 2026 · NCT01890486

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  • Atrium Health /ID# 267219, Charlotte
  • Atrium Health Wake Forest Baptist Medical Center /ID# 273142, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06428019

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • Duke University Medical Center, Durham
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • Duke University Medical Center, Durham
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876662

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  • University of North Carolina /ID# 233313, Chapel Hill
  • Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
  • Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT04895436

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

  • Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 17, 2025 · NCT04704323

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.